- Home
- ZTR vs AKBA Comparison
ZTR vs AKBA Comparison
Compare ZTR & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZTR | AKBA |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.5M | 375.0M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ZTR | AKBA |
|---|---|---|
| Price | $6.70 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.25 |
| AVG Volume (30 Days) | 166.7K | ★ 2.3M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.97 | $1.14 |
| 52 Week High | $7.11 | $4.08 |
Technical Indicators
Market Signals| Indicator | ZTR | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 49.33 |
| Support Level | $6.48 | $1.30 |
| Resistance Level | $6.92 | $1.56 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 3.51 | 33.90 |
Price Performance
Historical ComparisonAbout ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.